Identification of Post-Traumatic Stress Disorder in Adult Patients With Substance Use Disorders
Launched by HÔPITAL NOVO · May 22, 2024
Trial Information
Current as of February 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Between 61% and 81% of men and 51% to 74% of women are exposed to a traumatic event in their lifetime. These events may be brief and discrete, prolonged and/or recurrent, and may be direct or indirect. Direct or indirect exposure to traumatic events can lead to serious negative psychological consequences, including post-traumatic stress disorder (PTSD) and complex post-traumatic stress disorder (CPTSD). People exposed to complex traumatic events are at risk not only of suffering from PTSD or Complex PTSD, but also from other mental health co-morbidities, such as substance use disorders (dru...
Gender
ALL
Eligibility criteria
- Inclusion Criteria :
- • Patient aged 18 or over
- • Patient followed up at the adult Medical and Psychological Centre in the centres taking part in the study
- • Patient suffering from disorders related to the use of alcohol, cannabis, opiates, inhalants, sedatives, hypnotics, anxiolytics, stimulants, hallucinogens (all of these disorders will have been diagnosed by a doctor before or during follow-up according to DSM 5 criteria).
- • Patient aware of their substance use disorders
- • Patient informed and did not object to participating in the study
- Exclusion Criteria :
- • Patient previously diagnosed with PTSD or CPTSD
- • Patient agitated and/or aggressive
- • Patient under guardianship/curators
- • Patient who do not speak or understand French
Trial Officials
Déborah DELABY
Principal Investigator
Isarien Hospital Centre
About Hôpital Novo
Hôpital Novo is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative studies and rigorous scientific methodologies. With a strong emphasis on collaboration and ethical practices, Hôpital Novo partners with healthcare professionals and institutions to conduct high-quality clinical trials across various therapeutic areas. Their commitment to patient safety, data integrity, and regulatory compliance ensures that all research initiatives are conducted to the highest standards, ultimately contributing to the development of new treatments and therapies that enhance healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beaumont Sur Oise, , France
Clermont, , France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0